The expert panel advising the US Food and Drug Administration (FDA) this evening (Thursday) unanimously voted to recommend a modern company's corona vaccine for an booster dose for the elderly population and at risk of a serious illness, Reuters reported.
On Friday, another session of the advisory body to the Food and Drug Administration is expected to take place and discuss the recommendation of the Johnson & Johnson vaccine as a booster dose for the elderly and at-risk population in the United States.
If the Food and Drug Administration accepts the recommendation, as is usually the case, the American Center for Contagious Disease Control (CDC) will publish a specific label for the third modern-day vaccine.
The center's consultants are expected to meet and discuss the issue as early as next week.
Moderna submitted the request along with a proposal to give a third booster dose at half the amount given in the first two vaccine shots (40 micrograms), which is still more than the booster dose of Pfizer, which underwent the approval procedure for administration to the elderly population and at a risk of 30 micrograms.
Professional figures in the United States are under pressure from the political system to allow impulses to be given to curb the spread of the Delta variant in the country, after more than 700,000 people died in the United States as a result of the corona plague.